| James Peter Cornetet, MD | |
|
801 N 29th St, Billings, MT 59101-0905 | |
| (406) 238-2500 | |
| Not Available |
| Full Name | James Peter Cornetet |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 28 Years |
| Location | 801 N 29th St, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306868153 | NPI | - | NPPES |
| 0096968 | Medicaid | MT | |
| P00209306 | Other | RAILROAD MEDICARE | |
| 000099295 | Other | MT | BLUE CROSS/BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 9800 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Billings Clinic | Billings, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Billings Clinic | 6002993516 | 659 |
News Archive
Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.
QLT Inc. today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in pediatric patients with Leber Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.
In a study of the 9 largest U.S. cities, researchers at Columbia University Mailman School of Public Health found stark racial, ethnic, and socioeconomic inequities in COVID-19 vaccination rates across neighborhoods.
Using a blood test and a decision algorithm, rather than standard hospital protocols, to determine the appropriate length of antibiotic therapy in patients with severe sepsis or septic shock can reduce duration of treatments, shorten ICU stays, and lower hospital costs - all without adverse effects on patients, according to new research.
› Verified 2 days ago
| Entity Name | Billings Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326104845 PECOS PAC ID: 6002993516 Enrollment ID: O20080430000212 |
News Archive
Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.
QLT Inc. today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in pediatric patients with Leber Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.
In a study of the 9 largest U.S. cities, researchers at Columbia University Mailman School of Public Health found stark racial, ethnic, and socioeconomic inequities in COVID-19 vaccination rates across neighborhoods.
Using a blood test and a decision algorithm, rather than standard hospital protocols, to determine the appropriate length of antibiotic therapy in patients with severe sepsis or septic shock can reduce duration of treatments, shorten ICU stays, and lower hospital costs - all without adverse effects on patients, according to new research.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Peter Cornetet, MD Po Box 35100, Billings, MT 59107-5100 Ph: (406) 238-2500 | James Peter Cornetet, MD 801 N 29th St, Billings, MT 59101-0905 Ph: (406) 238-2500 |
News Archive
Researchers from the Jacks Laboratory at MIT's Koch Institute for Integrative Cancer Research (KI) have developed and characterized a genetically engineered mouse that successfully models progression from papillary thyroid cancer, which has an excellent prognosis, to anaplastic thyroid cancer (ATC), a highly lethal disease.
QLT Inc. today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in pediatric patients with Leber Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.
In a study of the 9 largest U.S. cities, researchers at Columbia University Mailman School of Public Health found stark racial, ethnic, and socioeconomic inequities in COVID-19 vaccination rates across neighborhoods.
Using a blood test and a decision algorithm, rather than standard hospital protocols, to determine the appropriate length of antibiotic therapy in patients with severe sepsis or septic shock can reduce duration of treatments, shorten ICU stays, and lower hospital costs - all without adverse effects on patients, according to new research.
› Verified 2 days ago
Jerald A. Bell, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2501 | |
Deborah G. Keenum, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Daniel T. Weaver, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
James S. Good, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2825 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
James Randall, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1221 N 26th St, Billings, MT 59101 Phone: 406-252-5681 Fax: 406-252-5025 | |
James Thomas Priddy, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4033 Avenue B, Billings, MT 59106 Phone: 406-256-6000 Fax: 406-256-9006 |